Patent ID: 9636400
Date: 2017-05-02
CPC Classifications: A61K,A61P,C07K

Claim:
1. A formulation comprising: (a) 5-200 mg/mL of a VEGF-specific fusion protein antagonist; (b) 1-50 mM of a buffer; (c) 25-150 mM or 0.5-30% of a stabilizer; and (d) 0.0005-5% of a polysorbate; wherein said VEGF-specific fusion protein antagonist represents at least 90% of the total weight of protein in the formulation, at least 90% of the total weight of VEGF-specific fusion protein antagonist is not present as an aggregate, said VEGF-specific fusion protein antagonist comprises an Ig domain 2 of human VEGF receptor 1, an Ig domain 3 of human VEGF receptor 2, and a multimerizing component, said VEGF-specific fusion protein antagonist does not comprise amino acids 1-26 of SEQ ID NO:4, and said Ig domain 2 of human VEGF receptor 1 consists essentially of amino acids 30-130 of SEQ ID NO:4, said Ig domain 3 of human VEGF receptor 2 consists essentially of amino acids 129-230 of SEQ ID NO:4, and said multimerizing component consists essentially of amino acids 232-457 of SEQ ID NO:4.